LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

Search

Biogen Inc

Ouvert

SecteurSoins de santé

137.84 0.31

Résumé

Variation du prix de l'action

24h

Actuel

Min

135.28

Max

137.65

Chiffres clés

By Trading Economics

Revenu

394M

635M

Ventes

215M

2.6B

P/E

Moyenne du Secteur

13.46

35.69

BPA

3.02

Marge bénéficiaire

23.995

Employés

7,605

EBITDA

457M

1B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+21.72% upside

Dividendes

By Dow Jones

Prochains Résultats

29 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.9B

21B

Ouverture précédente

137.53

Clôture précédente

137.84

Sentiment de l'Actualité

By Acuity

50%

50%

131 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Biogen Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 sept. 2025, 18:25 UTC

Principaux Mouvements du Marché

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28 sept. 2025, 23:48 UTC

Market Talk

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28 sept. 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28 sept. 2025, 23:45 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28 sept. 2025, 23:34 UTC

Market Talk

Oil Falls on Likely Technical Correction -- Market Talk

27 sept. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 sept. 2025, 21:56 UTC

Acquisitions, Fusions, Rachats

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 sept. 2025, 20:54 UTC

Résultats

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 sept. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 sept. 2025, 20:27 UTC

Acquisitions, Fusions, Rachats

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 sept. 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 sept. 2025, 19:53 UTC

Acquisitions, Fusions, Rachats

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept. 2025, 19:40 UTC

Résultats

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 sept. 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 sept. 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 sept. 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 sept. 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26 sept. 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 sept. 2025, 18:50 UTC

Market Talk
Résultats

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 sept. 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26 sept. 2025, 18:02 UTC

Acquisitions, Fusions, Rachats

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 sept. 2025, 18:02 UTC

Acquisitions, Fusions, Rachats

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 sept. 2025, 18:02 UTC

Acquisitions, Fusions, Rachats

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 sept. 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 sept. 2025, 16:56 UTC

Market Talk
Résultats

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 sept. 2025, 16:41 UTC

Market Talk
Résultats

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 sept. 2025, 16:26 UTC

Résultats

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Biogen Inc prévision

Objectif de Prix

By TipRanks

21.72% hausse

Prévisions sur 12 Mois

Moyen 167.2 USD  21.72%

Haut 224 USD

Bas 118 USD

Basé sur 26 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

26 ratings

12

Achat

14

Maintien

0

Vente

Score Technique

By Trading Central

118.15 / 121.17Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

131 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat